Skip to main content

ASCO 2017 Highlights

ASCO President Urges Oncology Providers to Prioritize Education, Care Delivery, Survivorship Care

By Wayne Kuznar

ASCO 2017 Highlights

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017

Alternative Payment Models and the Dangers of 2-Sided Risk

ASCO 2017 Highlights

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017

Alternative Payment Models May Drastically Affect Drug Manufacturers, Reduce Innovation

ASCO 2017 Highlights

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017

Business of Practice 2017: Maximize Your MIPS Success

By Chase Doyle; Chase Doyle

ASCO 2017 Highlights, Reimbursement

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017

Improving Communication Skills to Address Patient Goals Related to End-of-Life Care

ASCO 2017 Highlights

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017

FDA Perspective on Safety Reporting of Serious Adverse Events

ASCO 2017 Highlights

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017

Novel Drug “Home Run” for TRK Mutation–Positive Tumors

By Phoebe Starr

ASCO 2017 Highlights

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017

Pembrolizumab Makes Inroads in Sarcoma Subtypes

By Phoebe Starr

ASCO 2017 Highlights

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017

Abiraterone a Game-Changer in the Frontline Treatment of Advanced Prostate Cancer

By Wayne Kuznar

ASCO 2017 Highlights

August 2017, Vol 7, No 8: Special Edition – Highlights from ASCO 2017

ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year

By Eileen Koutnik-Fotopoulos

ASCO 2017 Highlights, Immunotherapy

July 2017, Vol 7, No 7

Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. Read More ›